Workflow
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
SMCSummit Midstream Partners, LP(SMC) Newsfile·2024-12-19 12:45
          Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentrationDecember 19, 2024 7:45 AM EST | Source: Phio Pharmaceuticals Corp.Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnol ...